<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="34532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657031</url>
  </required_header>
  <id_info>
    <org_study_id>EM 2015.13</org_study_id>
    <nct_id>NCT02657031</nct_id>
  </id_info>
  <brief_title>The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine</brief_title>
  <official_title>The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center of Southern Nevada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center of Southern Nevada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the efficacy of low dose Ketamine versus Compazine for the control of
      headache in patients presenting to the Emergency Department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After enrollment, each patient will randomized either to the standard treatment arm to
      receive prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV, OR to the study arm
      to receive Ketamine 0.3 mg/kg along with ondansetron 4 mg IV. The diphenhydramine or
      ondansetron will be administered first, and immediately afterward the prochlorperazine or
      Ketamine will be administered. The prochlorperazine or Ketamine will be diluted in saline so
      that the total volume is 5 mL, and will be administered over 2 minutes. The diphenhydramine
      will be diluted in saline so that it is 2 mL (the same volume as the ondansetron). Both
      groups will also receive a 500 mL normal saline bolus after the study medications are
      administered. The ED pharmacist will be responsible for preparing the medications, using a
      double-blind protocol. He or she will record which arm the patient was randomized to. Only
      the pharmacist will have access to the randomization records and will not reveal the
      randomization until the end of the study. Emergency providers will be instructed not to
      administer any rescue medications for at least 30 minutes. The electronic medical record
      order will read &quot;randomized study medication&quot; (for the Ketamine or prochlorperazine) and
      &quot;randomized add-on medication&quot; (for the ondansetron or diphenhydramine).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2016</start_date>
  <completion_date type="Actual">March 21, 2017</completion_date>
  <primary_completion_date type="Actual">March 21, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-Blind Randomized Clinical Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>100 mm VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>100 mm VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>100 mm VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vomiting</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restlessness</measure>
    <time_frame>0-60 minutes</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Headache</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Sailing 500 cc bolus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine</intervention_name>
    <description>prochlorperazine 10 mg IV</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Compazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 0.3 mg/kg IV</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydromine</intervention_name>
    <description>Diphenhydromine 25 mg IV</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron 4 mg IV</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline 500 cc IV Bolus</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Temperature &lt; 100.4Â° F

          -  Diastolic Blood Pressure &lt;104 mm Hg

          -  Normal neurological exam and mormal mental status

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Meningeal signs are present

          -  Acute angle closure glaucoma is suspected.

          -  Head trauma within the previous two weeks

          -  Lumbar puncture within the previous two weeks

          -  Thunderclap onset of the headache

          -  Weight more than 150 kg or less than 40 kg.

          -  Known allergy to one of the study drugs.

          -  History of schizophrenia or bipolar disorder.

          -  History of intracranial hypertension.

          -  Is a prisoner

          -  Patient declined informed consent

          -  Non-English speaking patient.

          -  Attending provider excludes patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Zitek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unviersity of Nevada School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>January 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Headache, Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Prochlorperazine</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This is a multi-center study that will share redacted data with investigators from the other site9s)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
